Needham & Co Initiates Coverage on Celsion Corporation (CLSN) with a Buy
More News related to CLSN
- Needham & Co Initiates Coverage on Celsion Corporation (CLSN) with a Buy
- Celsion Reports Third Quarter 2009 Financial Results and Business Update
- Trading Radar for 11/10: Tyco Int. (TYC), ArvinMeritor (ARM), Clearwire (CLWR), American Apparel (APP) Report
- Celsion to Hold Third Quarter 2009 Financial Results Conference Call Tuesday, November 10, 2009
- Celsion and Yakult Honsha Announce Treatment of First Patient in Japan in Celsion's Global Phase III ThermoDox(R) Trial for Primary Liver Cancer
Needham & Co initiates coverage on Celsion Corporation (Nasdaq: CLSN) with a Buy rating. Price target $7.
To see more analyst ratings on CLSN Click Here.
Celsion Corporation, an oncology drug development company, develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology.
Related Categories
New CoverageStocks Mentioned
+0.03Related Entities
Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Celsion
Mike on Nov 12, 2009 09:59 AMWhat is the rational of the upgrade. Their loss widens. No other news